Evidence map›Paper›PMID 36421328›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Teleoncology: A Solution for Everyone? A Single-Center Experience with Telemedicine during the Coronavirus Disease 2019 (COVID-19) Pandemic.

Paula Ribera, Sandra Soriano, Carla Climent, Laia Vilà, Ismael Macias, Luis Antonio Fernández-Morales, Julia Giner, Enrique Gallardo, Miquel Angel Segui Palmer, Carles Pericay

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paula RiberaDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.ORCID 0000-0002-3584-0582
Sandra SorianoDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Carla ClimentDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Laia VilàDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Ismael MaciasDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Luis Antonio Fernández-MoralesDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.ORCID 0000-0003-2120-6457
Julia GinerDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Enrique GallardoDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Miquel Angel Segui PalmerDepartment of Medical Oncology, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
Carles PericayDepartment of Medical Oncology, Hospital Universitari Mútua de Terrassa, 08221 Terrassa, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the beginning of the COVID-19 pandemic, the use of telehealth was rapidly implemented without previous evidence. The ONCOTELEMD study aimed to evaluate the opinion of patients attended via telemedicine during this period and to study factors that condition patient preferences on its use. Included patients had a confirmed cancer diagnosis and were contacted by telephone between 13 March and 30 April 2020, in the Medical Oncology Service of Hospital Parc Taulí, Sabadell. A 12-question survey was presented to them between 4 February and 19 April 2021. Statistical analysis was carried out using chi-square and multivariable logistic regression tests. Six hundred forty-six patients were included; 487 responded to the survey. The median age was 68 years (27-90), 55.2% were female. Most patients had a surveillance visit (65.3%) and were diagnosed with colorectal or breast cancer (43% and 26.5%, respectively); 91.8% of patients were satisfied, and 60% would accept the use of telemedicine beyond the pandemic. Patients aged more than 50 years (OR 0.40; 95% CI, 0.19-0.81;

Indexed as

Breast NeoplasmsCOVID-19TelemedicineAgedFemaleHealth PersonnelHumansMalePandemicsCOVID-19oncology carepandemicpatient caresatisfactiontelemedicineteleoncology

Identifiers

PMID36421328
PMCPMC9689494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.